This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajagopalan, P.
Right arrow Articles by Schinazi, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajagopalan, P.
Right arrow Articles by Schinazi, R. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 03 1996, 642-645, Vol 40, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks

P Rajagopalan, FD Boudinot, CK Chu, BC Tennant, BH Baldwin and RF Schinazi
Department of Pharmaceutics, University of Georgia, Athens 30602, USA.

The woodchuck (Marmota monax) has proven to be a suitable animal model for studying hepatitis B virus (HBV) infection owing to similarities in the course of infection between woodchuck hepatitis virus (WHV) in woodchucks and HBV in humans. (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine (3TC; lamivudine) is a nucleoside analog which has demonstrated antiviral activity against HBV as well as human immunodeficiency virus (HIV). The purpose of the present investigation was to characterize the pharmacokinetics of 3TC following intravenous and oral administration of 20 mg of 3TC per kg of body weight to woodchucks. Following intravenous administration, the concentrations of 3TC in plasma declined, with a terminal half-life of 2.84 +/- 0.85 h (mean +/- standard deviation). The systemic clearance and steady-state volume of distribution of 3TC were 0.22 +/- 0.078 liters/h/kg and 0.75 +/- 0.13 liters/kg, respectively. The renal clearance of the nucleoside analog was 0.063 +/- 0.016 liters/h/kg. The oral bioavailability of 3TC ranged from 18 to 54%. Allometric relationships between pharmacokinetic parameters and body weight developed by Hussey et al. (E.K. Hussey, K.H. Donn, M.J. Daniel, S.T. Hall, A.J. Harker, and G.L. Evans, J. Clin. Pharmacol. 34:975-977, 1994) were augmented by including data from woodchucks, monkeys (S.M. Blaney, M.J. Daniel, A.J. Harker, K. Godwin, and F.M. Balis, Antimicrob. Agents Chemother. 39:2779-2782, 1995), and additional data from rats (P. Rajagopalan, L. Moore, C.K. Chu, R.F. Schinazi, and F.D. Boudinot, submitted for publication). Interspecies scaling of the pharmacokinetic parameters of 3TC demonstrated a good correlation between clearance (0.74 . W0.76 [where W is body weight]; r = 0.93; P < 0.025), apparent volume of distribution (1.62 . W0.81; r = 0.98; P < 0.005), and steady-state volume of distribution (1.09 . W0.94; r = 0.99; P < 0.05) and species body weight. The allometric relationships for clearance and volume of distribution at steady state predicted the observed pharmacokinetic parameters in humans quite well; however, the apparent volume of distribution was underestimated in humans. Thus, the pharmacokinetic data obtained with the woodchuck HBV animal model should be useful for designing clinical trials.


This article has been cited by other articles:

  • Michalak, T. I., Zhang, H., Churchill, N. D., Larsson, T., Johansson, N.-G., Oberg, B. (2009). Profound Antiviral Effect of Oral Administration of MIV-210 on Chronic Hepadnaviral Infection in a Woodchuck Model of Hepatitis B. Antimicrob. Agents Chemother. 53: 3803-3814 [Abstract] [Full Text]  
  • Le Guerhier, F., Pichoud, C., Jamard, C., Guerret, S., Chevallier, M., Peyrol, S., Hantz, O., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F. (2001). Antiviral Activity of {beta}-L-2',3'-Dideoxy-2',3'-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus. Antimicrob. Agents Chemother. 45: 1065-1077 [Abstract] [Full Text]  
  • Bryant, M. L., Bridges, E. G., Placidi, L., Faraj, A., Loi, A.-G., Pierra, C., Dukhan, D., Gosselin, G., Imbach, J.-L., Hernandez, B., Juodawlkis, A., Tennant, B., Korba, B., Cote, P., Marion, P., Cretton-Scott, E., Schinazi, R. F., Sommadossi, J.-P. (2001). Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 45: 229-235 [Abstract] [Full Text]  
  • Korba, B. E., Schinazi, R. F., Cote, P., Tennant, B. C., Gerin, J. L. (2000). Effect of Oral Administration of Emtricitabine on Woodchuck Hepatitis Virus Replication in Chronically Infected Woodchucks. Antimicrob. Agents Chemother. 44: 1757-1760 [Abstract] [Full Text]  
  • Zhou, T., Saputelli, J., Aldrich, C. E., Deslauriers, M., Condreay, L. D., Mason, W. S. (1999). Emergence of Drug-Resistant Populations of Woodchuck Hepatitis Virus in Woodchucks Treated with the Antiviral Nucleoside Lamivudine. Antimicrob. Agents Chemother. 43: 1947-1954 [Abstract] [Full Text]  
  • Hurwitz, S. J., Tennant, B. C., Korba, B. E., Gerin, J. L., Schinazi, R. F. (1998). Pharmacodynamics of (-)-beta -2',3'-Dideoxy-3'-Thiacytidine in Chronically Virus-Infected Woodchucks Compared to Its Pharmacodynamics in Humans. Antimicrob. Agents Chemother. 42: 2804-2809 [Abstract] [Full Text]